West Pharma (WST) Misses Q4 EPS by 1c; Issues Light FY15 EPS Outlook

West Pharma (NYSE: WST) reported Q4 EPS of $0.45, $0.01 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $349.8 million versus the consensus estimate of $348.33 million.

West Pharma sees FY2015 EPS of $1.74-$1.92, versus the consensus of $1.97. West Pharma sees FY2015 revenue of $1.43-1.46 billion, versus the consensus of $1.48 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Berenberg Starts Brooks Macdonald Group PLC (BRK:LN) at Buy
• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM